Pharmacologic treatment of SARS: Current knowledge and recommendations

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 6, 2007, Pages 438-443

  Tai, Dessmon Y H ^a,b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Corticosteroid; Interferon; Protease inhibitor; Ribavirin; SARS

Indexed keywords

ALPHA INTERFERON; CHINESE DRUG; CORTICOSTEROID; GLYCYRRHIZIC ACID; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NICLOSAMIDE; PENTOXIFYLLINE; PREDNISOLONE; PROTEINASE INHIBITOR; RIBAVIRIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALOPECIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ASTHENIA; AVASCULAR NECROSIS; BRADYCARDIA; CANADA; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRY SKIN; DYSPNEA; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION SENSITIVITY; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER DYSFUNCTION; MYCOSIS; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OXYGEN CONSUMPTION; PANCREATITIS; PARESTHESIA; PHARYNGITIS; PLASMAPHERESIS; PNEUMONIA; PRACTICE GUIDELINE; PRURITUS; PULSATILE DRUG RELEASE; RADIODIAGNOSIS; RASH; RETICULOCYTOSIS; REVIEW; RHINITIS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SLEEP DISORDER; STANDARD; TASTE DISORDER; TERATOGENICITY; THORAX PAIN; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VISUAL IMPAIRMENT; VOMITING;

EID: 34547764400     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
2. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9. Erratum in: JAMA 2003;290:334.
3. Lew TW, Kwek TK, Tai DY, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:374-80.
4. Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE. Severe acute respiratory syndrome. Clin Infect Dis 2004;38:1420-7.
5. Tai DYH. Severe acute respiratory syndrome. Medical Progress 2005;32:317-24.
6. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, et al. Critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:367-73.
7. Tai DYH. Critically ill patients with SARS: clinical features, outcomes and prognostic features. Proceedings of 11th International Symposium on Shock and Critical Care; 13-15 August 2004; Bali, Indonesia. Indonesian Foundation of Critical Care Medicine, 2004:73-4.
8. Rubenfeld GD. Is SARS just ARDS? JAMA 2003;290:397-9.
9. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (Based on data as of 31 December 2003). Available at: http://www.who.int/csr/sars/country/table2004_04_21/en. Accessed 6 January 2005.
10. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414-20.
11. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773-8.
12. Lam KW. Severe acute respiratory syndrome in Hong Kong. J R Coll Physicians Edin 2003;33:83-9.
13. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ 2003;168:1289-92.
14. Levy MM, Baylor MS, Bernard GR, Fowler R, Franks TJ, Hayden FG, et al. Clinical issues and research in respiratory failure from severe acute respiratory syndrome. Am J Respir Crit Care Med 2005;171:518-26.
15. Rainer TH. Severe acute respiratory syndrome: clinical features, diagnosis, and management. Curr Opin Pulm Med 2004;10:159-65.
16. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
17. Lam WK, Tsang KWT. The severe acute respiratory syndrome - what lessons have been learned? J R Coll Physicians Edin 2004;34:90-8.
18. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-7.
19. Tsang KW, Mok TY, Wong PC, Ooi GC. Severe acute respiratory syndrome (SARS) in Hong Kong. Respirology 2003;8:259-65.
20. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
21. Chan-Yeung M, Ooi GC, Hui DS, Ho PL, Tsang KW. Severe acute respiratory syndrome. Int J Tuberc Lung Dis 2003:7:1117-30.
22. Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003;326:1358-62.
23. Lapinsky SE, Hawryluck L. ICU management of severe acute respiratory syndrome. Intensive Care Med 2003;29:870-5.
24. Knowles SR, Philips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37:1139-42.
25. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168:1449-56.
26. Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, Kuo HT, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005;128:263-72.
27. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361:2045-6.
28. Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9:713-7.
29. Mazzulli T, Farcas GA, Poutanen SM, Willey BM, Low DE, Butany J, et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis 2004;10:20-4.
30. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
31. Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med 2004;4:152-60.
32. Lim WS, Anderson SR, Read RC; SARS Guidelines Committee of the British Thoracic Society; British Infection Society; Health Protection Agency. Hospital management of adults with severe acute respiratory syndrome (SARS) if SARS re-emerges - updated 10 February 2004. J Infect 2004;49:1-7.
33. Charles M. Severe acute respiratory syndrome (SARS) and coronavirus testing - United States, 2003. The CDC SARS Investigative Team. MMWR Morb Mort Wkly Rep 2003;52:297-302.
34. Zhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome (SARS). Am J Respir Crit Care Med 2003;168:7-9.
35. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003;228:395-400.
36. Tsang KW, Lam WK. Management of severe acute respiratory syndrome: The Hong Kong University Experience. Am J Respir Crit Care Med 2003;168:417-24.
37. Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology 2003;8:S25-S30.
38. Zheng ZG, Zhong NS. The use of corticosteroid in management of critical SARS. Chin Med J 2003; 42:676-77.
39. Tsang OT, Chau TN, Choi KW, Tso EY, Lim W, Chiu MC, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003;9:1381-7.
40. Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as a treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 2005;51:98-102.
41. Oba Y. The use of corticosteroids in SARS. N Engl J Med 2003;348:2034-5.
42. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507-8.
43. Tsang KW, Ooi GC, Ho PL. Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt? Eur Respir J 2004;24:1025-32.
44. Chan KS, Zheng JP, Mok YW, Li YM, Liu YN, Chu CM, et al. SARS: prognosis, outcome and sequelae. Respirology 2003;8:S36-S40.
45. Li SS, Cheng CW, Fu CL, Chan YH, Lee MP, Chan JW, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation 2003;108:1798-803.
46. Wong WM, Ho JC, Ooi GC, Mok T, Chan J, Hung IF, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS. JAMA 2003;290:2663-5.
47. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-20.
48. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290:3222-8.
49. Vastag B. Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA 2003;290:1695-6.
50. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Kao RY, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
51. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.
52. Ballow M. Mechanisms of action of intravenous serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997;100:151-7.
53. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-16.
54. Nachbaur D, Herold M, Gachter A, Neiderwieser D. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology 1998;94:279-83.
55. Chng HH, Leong KP, Leung B, Ang B, Leo YS, Loo S, et al. Intravenous immunoglobulin: potential role in the management of severe acute respiratory synfdrome. In: Dalakas MC, Spath PJ, editors. Intravenous Immunoglobulins in the Third Millennium. New York: Parthenon Publishing Group; 2004:331-6.
56. Ho JC, Wu AY, Lam B, Ooi GC, Khong PL, Ho PL, et al. Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 2004:8:1173-9.
57. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10:676-8.
58. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9:199-201.
59. Johnson MA, Pooley C, Ignajatovic J, Tyack SG. A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. Vaccine 2003;21:2730-6.
60. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-6.
61. Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. N Engl J Med 2003;348:1947-8.
62. Bernard GR. Corticosteroids: the "terminator" of all untreatable serious pulmonary illness. Am J Respir Crit Care Med 2003;168:1409-10.